3-fluoro-4-(thiophen-2-yl)phenol | 1261963-39-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-fluoro-4-(thiophen-2-yl)phenol
• 英文别名: 3-fluoro-4-thiophen-2-ylphenol
• CAS: 1261963-39-6
• 化学式: C₁₀H₇FOS
• 分子量: 194.229
• InChiKey: GQJSELTYZHTQOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-fluoro-4-(thiophen-2-yl)phenol 在 氨基磺酰氯 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 生成 3-fluoro-4-(thiophen-2-yl)phenyl sulfamate
  参考文献：
  名称：

  First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases

  摘要：

  STS and 17 beta-HSD1 are attractive targets for the treatment of estrogen-dependent diseases like endometriosis and breast cancer. The simultaneous inhibition of both enzymes appears more promising than blockage of either protein alone. We describe a designed multiple ligand approach resulting in highly potent dual inhibitors. The most interesting compound 9 showed nanomolar IC50 values for both proteins, membrane permeability, and no interference with estrogen receptors. It efficiently reversed E1S- and E1-induced T47D cell proliferation.

  DOI：

  10.1021/acs.jmedchem.7b00062
• 作为产物：
  描述：

  2-(2-fluoro-4-methoxyphenyl)thiophene 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以97%的产率得到3-fluoro-4-(thiophen-2-yl)phenol
  参考文献：
  名称：

  First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases

  摘要：

  STS and 17 beta-HSD1 are attractive targets for the treatment of estrogen-dependent diseases like endometriosis and breast cancer. The simultaneous inhibition of both enzymes appears more promising than blockage of either protein alone. We describe a designed multiple ligand approach resulting in highly potent dual inhibitors. The most interesting compound 9 showed nanomolar IC50 values for both proteins, membrane permeability, and no interference with estrogen receptors. It efficiently reversed E1S- and E1-induced T47D cell proliferation.

  DOI：

  10.1021/acs.jmedchem.7b00062

文献信息

• BETA3 ADRENERGIC AGONISTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1303509A1

  公开（公告）日：2003-04-23
• [EN] BETA3 ADRENERGIC AGONISTS<br/>[FR] AGONISTES ADRENERGIQUES BETA3
  申请人：LILLY CO ELI

  公开号：WO2002006276A1

  公开（公告）日：2002-01-24

  The present invention relates to a β3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
• First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases
  作者：Mohamed Salah、Ahmed S. Abdelsamie、Martin Frotscher

  DOI：10.1021/acs.jmedchem.7b00062

  日期：2017.5.11

  STS and 17 beta-HSD1 are attractive targets for the treatment of estrogen-dependent diseases like endometriosis and breast cancer. The simultaneous inhibition of both enzymes appears more promising than blockage of either protein alone. We describe a designed multiple ligand approach resulting in highly potent dual inhibitors. The most interesting compound 9 showed nanomolar IC50 values for both proteins, membrane permeability, and no interference with estrogen receptors. It efficiently reversed E1S- and E1-induced T47D cell proliferation.